Sagimet Biosciences Inc.

NasdaqGM:SGMT Stock Report

Market Cap: US$165.2m

Sagimet Biosciences Past Earnings Performance

Past criteria checks 0/6

Sagimet Biosciences's earnings have been declining at an average annual rate of -16.5%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been growing at an average rate of 50.2% per year.

Key information

-16.5%

Earnings growth rate

64.8%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate50.2%
Return on equity-22.0%
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans

Dec 15
Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans

Sagimet: More Than Just A MASH Drug Development Biotech

Nov 14

Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat

Oct 18

Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide

Jul 31

Companies Like Sagimet Biosciences (NASDAQ:SGMT) Are In A Position To Invest In Growth

May 31
Companies Like Sagimet Biosciences (NASDAQ:SGMT) Are In A Position To Invest In Growth

Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity

Apr 26

Sagimet: Additional Upside Possible After Latest NASH Data Release

Jan 24

Revenue & Expenses Breakdown

How Sagimet Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:SGMT Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-381630
30 Jun 242-291622
31 Mar 242-281421
31 Dec 232-281320
30 Sep 232-271120
30 Jun 230-28722
31 Mar 230-28624
31 Dec 220-30625
31 Dec 210-24419
31 Dec 200-1138

Quality Earnings: SGMT is currently unprofitable.

Growing Profit Margin: SGMT is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SGMT is unprofitable, and losses have increased over the past 5 years at a rate of 16.5% per year.

Accelerating Growth: Unable to compare SGMT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SGMT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (23.5%).


Return on Equity

High ROE: SGMT has a negative Return on Equity (-21.98%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/06 11:00
End of Day Share Price 2025/02/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sagimet Biosciences Inc. is covered by 9 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrea TanGoldman Sachs
Andrea NewkirkGoldman Sachs
Antonio ArceH.C. Wainwright & Co.